A comparison of different antibiotic regimens for the treatment of infective endocarditis

Martí‐Carvajal, Arturo J; Dayer, Mark; Conterno, Lucieni de Oliveira; Garay, Alejandro G Gonzalez; Martí-Amarista, Cristina Elena

doi:10.1002/14651858.cd009880.pub3

Cited by 11 publications

(12 citation statements)

References 155 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent Cochrane review analyzed the evidence from six small clinical trials evaluating various antibiotic regimens for endocarditis with a range of etiologies. After an in-depth analysis, the authors of the review concluded that given the high risk of bias, insufficient data, or underpowered designs, the evidence offered by these trials did not support or reject any of the regimens evaluated ( 121 ). This poor evidence may partly explain the significant heterogeneity in the management of this disease observed in some surveys ( 122 ) and the lack of adherence to some recommendations of the European guidelines even among those who developed them ( 123 ).…”

Section: Managementmentioning

confidence: 99%

Current Challenges in the Management of Infective Endocarditis

et al. 2021

View full text Add to dashboard Cite

Infective endocarditis is a relatively rare, but deadly cause of sepsis, with an overall mortality ranging from 20 to 25% in most series. Although the classic clinical classification into syndromes of acute or subacute endocarditis have not completely lost their usefulness, current clinical forms have changed according to the profound epidemiological changes observed in developed countries. In this review, we aim to address the changing epidemiology of endocarditis, several recent advances in the understanding of the pathophysiology of endocarditis and endocarditis-triggered sepsis, new useful diagnostic tools as well as current concepts in the medical and surgical management of this disease. Given its complexity, the management of infective endocarditis requires the close collaboration of multidisciplinary endocarditis teams that must decide on the diagnostic approach; the appropriate initial treatment in the critical phase; the detection of patients needing surgery and the timing of this intervention; and finally the accurate selection of patients for out-of-hospital treatment, either at home hospitalization or with oral antibiotic treatment.

show abstract

Section: Managementmentioning

confidence: 99%

Current Challenges in the Management of Infective Endocarditis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Infective endocarditis (IE), especially infection with Methicillin-resistant Staphylococcus aureus (MRSA), is also an important risk factor for congestive HF ( Fernández-Hidalgo et al, 2018 ). Martí-Carvajal et al (2020) have conducted a comparison of different types of antibiotics for IE treatment and found vancomycin was very effective in inhibiting MRSA infection. However, patients with congestive HF sometimes exhibit reduced vancomycin clearance ( Shimamoto et al, 2013 ).…”

Section: Interventions Targeted At Microbial Metabolitesmentioning

confidence: 99%

Microbial metabolites and heart failure: Friends or enemies?

Liu

Zhou

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Heart failure (HF), a global health issue characterized by structural or functional cardiac dysfunction, which was found to be associated with the gut microbiome recently. Although multiple studies suggested that the gut microbiome may have an impact on the development of cardiovascular diseases, the underlying mechanism of the gut microbiome in HF remains unclear. The study of metabolites from gut microbiota influenced by dietary nutrition uptake suggested that gut microbiota may affect the process of HF. However, on the basis of the microbiota’s complicated roles and their interactions with metabolites, studies of microbial metabolites in HF had rarely been described so far. In this review, we focused on dietary nutrition-related factors that were involved in the development and progression of HF, such as trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and bile acids (BAs), to summarize their advances and several potential targets in HF. From a therapeutic standpoint, we discussed microbial metabolites as a potential strategy and their applications in HF as well.

show abstract

“…Various complications related to this disease have been reported, including infectious prosthetic valve endocarditis (IPVE), which often causes valve imbalance and unusability [11]. In addition, BE may cause neurological problems that affect approximately one-quarter of patients with the disease, and in most cases, asymptomatic lesions are detected [12].…”

Section: Complicationsmentioning

confidence: 99%